Impact of geographic and demographic characteristics on treatment with Lu-PSMA for metastatic castrate-resistant prostate cancer (mCRPC). Rucaparib vs docetaxel (DTX) or second-generation androgen ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback